None
]]>Inpatient hospitalization for patients age 18 and older discharged from inpatient care (non-elective admissions) with a principal diagnosis of ischemic or hemorrhagic stroke and a length of stay less than or equal to 120 days that ends during measurement period
]]>Inpatient hospitalization for patients who had antithrombotic therapy administered the day of or day after hospital arrival
]]>Not Applicable
]]>Inpatient hospitalizations for patients with a principal diagnosis of ischemic stroke
]]>- Inpatient hospitalizations for patients who have a duration of stay less than 2 days
- Inpatient hospitalization for patients with comfort measures documented day of or the day after arrival
- Inpatient hospitalization for patients with intra-venous or intra-arterial Thrombolytic (t-PA) Therapy administered within 24 hours prior to arrival or anytime during hospitalization
]]>- Inpatient hospitalization for patients with a documented reason for not administering antithrombotic therapy the day of or day after hospital arrival
- Inpatient hospitalization for patients who receive Prasugrel as an antithrombotic therapy the day of or day after hospital arrival
- Inpatient hospitalization for patients with an INR greater than 3.5
]]>Improvement noted as an increase in rate
]]>The effectiveness of antithrombotic agents in reducing stroke mortality, stroke-related morbidity and recurrence rates has been studied in several large clinical trials. While the use of these agents for patients with acute ischemic stroke and transient ischemic attacks (TIA) continues to be the subject of study, substantial evidence is available from completed studies. Data at this time suggest that antithrombotic therapy should be administered within 2 days of symptom onset in acute ischemic stroke patients to reduce stroke mortality and morbidity as long as no contraindications exist.
Aspirin is the recommended antithrombotic medication for early antithrombotic therapy and most frequently administered unless contraindicated. Anticoagulants at doses to prevent venous thromboembolism (VTE) are insufficient. Subcutaneous lovenox (enoxaparin) and unfractionated heparin (UFH) SQ at lower dosages used for VTE prophylaxis (i.e., enoxaparin SQ 40 mg once daily; enoxaparin SQ 30 mg Q12 hours; UFH 5,000 units or less two or three times daily) are not sufficient for early antithrombotic therapy.
Anticoagulants at doses to prevent VTE are insufficient antithrombotic therapy to prevent recurrent ischemic stroke or TIA.
]]>None
]]>None
]]>Antithrombotic therapy should be administered within 2 days of symptom onset in acute ischemic stroke patients to reduce stroke mortality and morbidity as long as no contraindications exist
]]>- Inpatient hospitalization for patients with comfort measures documented day of or the day after arrival
- Inpatient hospitalization for patients with intra-venous or intra-arterial Thrombolytic (t-PA) Therapy
administered within 24 hours prior to arrival or anytime during hospitalization
]]>- Inpatient hospitalization for patients who receive Prasugrel as an antithrombotic therapy the day of or day after hospital arrival.
- Inpatient hospitalization for patients with an international normalized ratio (INR) greater than 3.5.
]]>Aspirin is the recommended antithrombotic medication for early antithrombotic therapy and most frequently administered unless contraindicated. Anticoagulants at doses to prevent venous thromboembolism (VTE) are insufficient. Subcutaneous Lovenox (enoxaparin) and unfractionated heparin (UFH) SQ at lower dosages used for VTE prophylaxis (i.e., enoxaparin SQ 40 mg once daily; enoxaparin SQ 30 mg Q12 hours; UFH 5,000 units or less two or three times daily) are not sufficient for early antithrombotic therapy.
Anticoagulants at doses to prevent VTE are insufficient antithrombotic therapy to prevent recurrent ischemic stroke or TIA.
]]>- Inpatient hospitalizations for patients with comfort measures documented day of or the day after arrival
- Inpatient hospitalizations for patients with intra-venous or intra-arterial Thrombolytic (t-PA) Therapy
administered within 24 hours prior to arrival or anytime during hospitalization
]]>- Inpatient hospitalizations for patients who receive Prasugrel as an antithrombotic therapy the day of or day after hospital arrival.
- Inpatient hospitalizations for patients with an international normalized ratio (INR) greater than 3.5.
]]>Aspirin is the recommended antithrombotic medication for early antithrombotic therapy and most frequently administered unless contraindicated. Anticoagulants at doses to prevent venous thromboembolism (VTE) are insufficient. Subcutaneous Lovenox (enoxaparin) and unfractionated heparin (UFH) SQ at lower dosages used for VTE prophylaxis (i.e., enoxaparin SQ 40 mg once daily; enoxaparin SQ 30 mg Q12 hours; UFH 5,000 units or less two or three times daily) are not sufficient for early antithrombotic therapy.
Anticoagulants at doses to prevent VTE are insufficient antithrombotic therapy to prevent recurrent ischemic stroke or TIA.
]]>